Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-22-000730

Chief Scientific Officer sold 1,828 shares at $28.96 ($52,939)

  • Chief Scientific Officer acquired 1,828 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Hansen Gwenn · Chief Scientific Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2022-01-03 Exercise or conversion : show line 1 in the form +400 $7.26 $2,904 14,597 D
2022-01-03 Exercise or conversion : show line 2 in the form +1,428 $9.57 $13,666 16,025 D
2022-01-03 Sale : show line 3 in the form −1,828 $28.96 $52,939 14,197 D
Open-market sales · 1,828 sh · avg $28.96 · $52,939

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2022-01-03 Exercise or conversion : show line 4 in the form Employee Stock Option (right to buy) −400 67,466 D
2022-01-03 Exercise or conversion : show line 5 in the form Employee Stock Option (right to buy) −1,428 81,905 D
Loading xslF345X03/doc4.xml…